| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB400-135SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-27293SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-78039SS | |||
| Azide and BSA Free | NBP2-80921 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-78162SS | |||
| Azide and BSA Free | NBP2-81010 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-44307SS | |||
| Azide and BSA Free | NBP2-80669 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-27184SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-29626SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB400-136SS | |||
![Western Blot: CHREBP Antibody - BSA Free [NB400-135] - CHREBP Antibody [NB400-135] - Mouse liver tissue lysate, 10 ug total protein per lane, probed with CHREBP antibody. Specific bands at ~150 kDa (some wells as doublets). Weaker bands at ~45 kDa, very faint bands at ~100 kDa. These bands were absent after exposure to ChREBP blocking peptide, although some faint non-specific banding remained at ~90, ~60, and ~40 kDa. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/CHREBP-Antibody---BSA-Free-Western-Blot-NB400-135-img0023.jpg "Western Blot: CHREBP Antibody - BSA Free [NB400-135] - CHREBP Antibody [NB400-135] - Mouse liver tissue lysate, 10 ug total protein per lane, probed with CHREBP antibody. Specific bands at ~150 kDa (some wells as doublets). Weaker bands at ~45 kDa, very faint bands at ~100 kDa. These bands were absent after exposure to ChREBP blocking peptide, although some faint non-specific banding remained at ~90, ~60, and ~40 kDa. WB image submitted by a verified customer review.")
![Immunocytochemistry/Immunofluorescence: CHREBP Antibody - BSA Free [NB400-135] - CHREBP Antibody [NB400-135] - RetSat depletion prevents the glucose-induced nuclear accumulation of ChREBP independent of 13,14-dihydroretinol generation. Hepatocytes were treated with Control or RetSat siRNA overnight. The next morning, cells were incubated with vehicle (DMSO) or 1 uM 13,14-dhretinol for 24 h at the indicated glucose concentrations and mRNA expression of Txnip determined by qPCR. Data are shown as mean +/- s.d., n = 4. Two-way ANOVA with Bonferroni post test revealed significances between low and high glucose (#P < 0.05) and between siControl and siRetSat (*P < 0.05), treatment with 13,14-dhretinol had no effect. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-017-00430-w), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CHREBP-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB400-135-img0021.jpg)
![Immunohistochemistry-Paraffin: CHREBP Antibody - BSA Free [NB400-135] - CHREBP Antibody [NB400-135] - Staining of human colon, epithelium at a 40X magnification.](http://images.novusbio.com/fullsize/CHREBP-Antibody---BSA-Free-Immunohistochemistry-Paraffin-NB400-135-img0016.jpg)
![Chromatin Immunoprecipitation: CHREBP Antibody - BSA Free [NB400-135] - CHREBP Antibody [NB400-135] - Effects of glucose on ChREBP binding.HepG2 cells were treated with low (2.7 mM) and high (25 mM) glucose for 8 h. Chromatin was isolated and fragmented, and ChIP was performed with control IgG or anti-ChREBP antibody. Validated primers for each gene were used for quantitative real-time PCR. The data presented as fold increase for the signal from anti-ChREBP relative to control IgG. The negative control, Cyclo, showed no enrichment (data not shown). Values represent the mean +/- S.D. of three independent samples. *p<0.005 vs. IgG, #p<0.0001 vs. 2.7 mM glucose with anti-ChREBP. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0022544), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CHREBP-Antibody---BSA-Free-Chromatin-Immunoprecipitation-NB400-135-img0018.jpg)
![Western Blot: CHREBP Antibody - BSA Free [NB400-135] - CHREBP Antibody [NB400-135] - Detection of ChREBP in 20 ug of human hepatocyte lysate using NB400-135. 5-10 second film exposure.](http://images.novusbio.com/fullsize/CHREBP-Antibody---BSA-Free-Western-Blot-NB400-135-img0007.jpg)
![Western Blot: CHREBP Antibody - BSA Free [NB400-135] - CHREBP Antibody [NB400-135] - Detection of ChREBP in liver nuclear extracts from well-fed rats. 7% SDS-PAGE gel, 1:1000 dilution of NB400-135. Photo courtesy of Dr. Uyeda, UT Southwestern University.](http://images.novusbio.com/fullsize/CHREBP-Antibody---BSA-Free-Western-Blot-NB400-135-img0010.jpg)
![Western Blot: CHREBP Antibody - BSA Free [NB400-135] - CHREBP Antibody [NB400-135] - RetSat depletion in mouse liver reduces protein levels and target gene expression of ChREBP. RetSat and ChREBP protein expression by immunoblotting. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-017-00430-w), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CHREBP-Antibody---BSA-Free-Western-Blot-NB400-135-img0019.jpg)
![Western Blot: CHREBP Antibody - BSA Free [NB400-135] - CHREBP Antibody [NB400-135] - Protein expression levels of carbohydrate-responsive element-binding protein (ChREBP), in livers of rats receiving normal water (CON), a 13% (w/v) glucose solution (GLU), a 13% (w/v) fructose solution (FRUC), or a 0.4% (w/v) aspartame solution (n = 6 per diet group). All data were normalized to beta-actin expression levels and are expressed relative to the controls (CON). Data are expressed as means +/- SEM. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. CON; +p < 0.05, ++p < 0.01, +++p < 0.001 vs. ASP; p < 0.01, p < 0.001 vs. GLU. Image collected and cropped by CiteAb from the following publication (//www.mdpi.com/2072-6643/9/5/476), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CHREBP-Antibody---BSA-Free-Western-Blot-NB400-135-img0020.jpg)
![Immunocytochemistry/Immunofluorescence: CHREBP Antibody - BSA Free [NB400-135] - CHREBP Antibody [NB400-135] - HeLa cells were fixed for 10 minutes using 10% formalin and permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti-ChREBP (NB400-135) at a 1:200 dilution overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:500 dilution. Alpha tubulin was used as a co-stained at 1:1000 and detected with an anti-mouse DyLight 550 (Red) at a 1:500. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/CHREBP-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB400-135-img0017.jpg)
![Immunohistochemistry: CHREBP Antibody - BSA Free [NB400-135] - CHREBP Antibody [NB400-135] - Analysis of CHREBP in mouse liver using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/CHREBP-Antibody---BSA-Free-Immunohistochemistry-NB400-135-img0013.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: CHREBP Antibody - BSA Free [NB400-135] - Immunoblot analysis of ChREBP in liver lysates of control and L-Chrebp -/- mice. Aliquots (60 ug of protein) of liver whole-cell lysates were subjected to SDS-PAGE and immunoblot analysis with anti-ChREBP and anti-calnexin antibodies. ChREBP delta denotes a truncated aberrant ChREBP protein present only in lysates prepared from L-Chrebp -/- livers. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29335275/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CHREBP Antibody - BSA Free-Knockout Validated-NB400-135-img0024.jpg)
![Western Blot: CHREBP Antibody - BSA Free [NB400-135] - Raffinose stimulates transcription of genes involved in epidermal barrier function in HaCaT cells.(a & b) HaCaT cells were treated with vehicle, 1 μM or 10 μM raffinose (Raf), or 1 μM TO901317 (T17) for 24 h. Expressions of transcripts (a) & proteins (b) were analyzed by qRT-PCR or western blotting, respectively. FLG; filaggrin. IVL; involucrin, LOR; loricrin, AQP3; aquaporin3. (c) HaCaT cells were transfected with siGFP control, siLXR alpha , or siLXR beta , & then treated with 1 μM raffinose for 24 h. Expression of proteins was analyzed by western blotting. The original blots are shown in Supplementary Fig. S9. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28266648), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-135_rabbit-polyclonal-chrebp-antibody-310202415291928.jpg)
![Immunohistochemistry-Paraffin: CHREBP Antibody - BSA Free [NB400-135] - Impaired hepatic SIRT1-FoxO signaling in L-G6pc-/- mice.(A) Western blots & densitometry analysis (n = 5), & quantification of mRNA for hepatic SIRT1 & FoxO3a (n = 8). (B) Hepatic NAD+ levels (n = 9). (C) Western blots & densitometry analysis of PPAR-gamma , PPAR-alpha & beta -actin (n = 5). (D) Immunohistochemical analysis of hepatic ChREBP & quantification of nuclear ChREBP-translocated cells (n = 4). Scale bar, 25 μm. (E) Quantification of mRNA for hepatic Acaca, Fasn & Elovl6 by real-time RT-PCR (n = 6). (F) Western blots of acetylated & total FoxO3a after immunoprecipitation of nuclear extracts using anti-FoxO3a, & quantification of the acetylated FoxO3a/total FoxO3a (n = 5). Data represent the mean ± SEM. *P < 0.05, **P < 0.005. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28558013), licensed under a CC0-1.0 license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-135_rabbit-polyclonal-chrebp-antibody-310202415171345.jpg)
![Western Blot: CHREBP Antibody - BSA Free [NB400-135] - Expressing recombinant ChREBP beta in Rictor-deficient adipocytes rescues expression of DNL enzymes.Western blot of indicated proteins in differentiated adipocytes with or without Rictor deletion transfected with various rescue constructs that were stably expressed in cells before differentiation. ‘*' indicates ChREBP beta based on molecular weight. Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/ncomms11365), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-135_rabbit-polyclonal-chrebp-antibody-310202415171318.jpg)
![Western Blot: CHREBP Antibody - BSA Free [NB400-135] - Hepatic expression of mRNAs encoding carbohydrate response element-binding protein (ChREBP) (a), liver pyruvate kinase (LPK) (c), & microsomal triglyceride transfer protein (MTTP) (d), & nuclear ChREBP protein (b) in water-control, 10% fructose solution-control, & fructose pair-fed oleanolic acid- (OA-) treated rats at week 10. Animals were administered with OA (25 mg/kg/day) or vehicle (OA: 0 mg/kg, 5% Gum Arabic) by oral gavage daily for 10 weeks. mRNA was determined by real-time PCR. Protein expression was determined by Western blot. Data are means ± SEM (n = 6 each group). *P < 0.05. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23737835), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-135_rabbit-polyclonal-chrebp-antibody-31020241529337.jpg)
![Western Blot: CHREBP Antibody - BSA Free [NB400-135] - LXR mediate the induction of lipogenesis induced by an oleic acid-rich diet.(A) Hepatic Acly, Acaca, Acacb, Fasn, Elovl6, Scd1 mRNA levels quantified by qPCR. (B) Cytoplasmic protein expression levels of P-ACLY, ACLY, ACC, ELOVL6, SCD1, FASN & beta -ACTIN assayed by Western Blotting. (C) Fads1, Fads2, Elovl5, Gpat, Pnpla3 & Lpk mRNA quantification assayed by qPCR. (D) Srebp-1c & Chrebp mRNA quantification assayed by qPCR. (E) Cytoplasmic & nuclear expression levels of LXR, SREBP-1c & ChREBP assayed by Western Blotting. Data are the mean±SEM of values measured in LXR+/+ & LXR-/- mice fed REF or OLIV diet. a Significant genotype effect. b Significant difference versus REF diet (n = 6 mice per group). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28732092), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-135_rabbit-polyclonal-chrebp-antibody-31020241534316.jpg)
![Western Blot: CHREBP Antibody - BSA Free [NB400-135] - Analysis of protein levels in livers transfected with GK & GKA456V. Livers excised from mice in postabsorptive state were homogenized & resolved by Western blot. (a, b) Representative blots from three independent experiments. The densitometric analysis is presented (N = 4, *P < 0.05 versus pControl, ***P < 0.001 versus pGKA456V). (c) Liver sections of 5-hour fasted mice injected with pControl, pGK, or pGKA456V were immunostained with Glc6Pase antibody. TO-PRO-3 was used to visualize nuclei. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/22194744), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-135_rabbit-polyclonal-chrebp-antibody-310202415371929.jpg)
![Western Blot: CHREBP Antibody - BSA Free [NB400-135] - ChREBP knockdown inhibited glycolysis, lipogenesis & p21 in HT29 cells. (A) Inhibited relative mRNA expression of ChREBP alpha & ChREBP beta normalized to B2M after control or ChREBP siRNA transfection for 48 hours. (B) Western-blot of ChREBP, phospho-p53 & p21 & their quantification on the right. beta -actin was served as a loading control. Proteins were extracted from cells transfected with sicontrol & siChREBP after 48 hours. The quantification of western blot was normalized to beta -actin. (C) Decreased relative mRNA expression of glycolytic & lipogenic genes, normalized to B2M. (D) Relative mRNA expression of p53 & p21, normalized to B2M. (E) Relative mRNA expression of cell Cyclins, normalized to B2M. n = 4. *p < 0.05; **p < 0.01; ***p < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32144313), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-135_rabbit-polyclonal-chrebp-antibody-31020241528455.jpg)
![Western Blot: CHREBP Antibody - BSA Free [NB400-135] - Ligand-activated LXR reduces ChREBP binding to chromatin. (A). Left panels: Local pattern of LXR-ChREBP co-occupancy. Browser view of LXR & ChREBP tracks in the promoter region of Lpk (Pklr), Txnip, Fasn & Scd1. Square brackets indicate the scale maxima of ChIP/input ratios. Arrows indicate the genomic locations of quantitative RT-PCR primers. Right panel: AML12 cells transfected with ChREBP alpha /Mlx gamma & LXR alpha /RXR alpha were treated with DMSO (0.1%) or GW3965 (10 µM) for 18 h. ChREBP or LXR binding to genomic location indicated in the right panels were detected by ChIP using antibodies against ChREBP, LXR or IgG as negative control. Data are presented as mean ± SEM (n = 3–5). Significant differences are shown as * p < 0.05, ** p < 0.01, *** p < 0.001 compared to ChIP-IgG & #p < 0.05, ##p < 0.01, ###p < 0.001 between DMSO & GW3965 groups. ns, not significant. (B). CoIP of LXR alpha & ChREBP alpha , expressed in COS-1 cells cultured in 25 mM glucose, treated with DMSO (0.1%) or GW3965 (1 µM) for 18 h. Lysates were immunoprecipitated with ChREBP antibody (n = 3). Input & immunoprecipitated proteins were immunoblotted with ChREBP or LXR alpha antibodies. One representative western blot is shown. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32414201), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-135_rabbit-polyclonal-chrebp-antibody-310202416171431.jpg)
![Western Blot: CHREBP Antibody - BSA Free [NB400-135] - Induction of hepatic Srebp-1 & carbohydrate response element-binding protein (Chrebp) beta expression by dietary glucose is reduced in LXR alpha −/− mice. (A) Hepatic gene expression of Lxr alpha / beta , Srebp-1, & Chrebp alpha / beta was analyzed by quantitative RT-PCR & normalized to Tbp; (B) Cytosolic & nuclear lysates were immunoblotted with antibodies against LXR, SREBP-1, & ChREBP with alpha -Tubulin & Lamin A as loading controls. Each lane represents independent mice from each group. One representative western blot is shown (n = 3). Data represent the mean ± SEM (n = 5). Significant differences were found using two-way ANOVA followed by Tukey’s multiple comparison test (fasted vs. fructose fed & fasted vs. glucose fed RNA data were analyzed separately). * p < 0.05, ** p < 0.01, *** p < 0.001 compared to fasted. #p < 0.05, ##p < 0.01, ###p < 0.001 compared to LXR alpha +/+ mice. Image collected & cropped by CiteAb from the following publication (//www.mdpi.com/2072-6643/9/7/678), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-135_rabbit-polyclonal-chrebp-antibody-3102024161891.jpg)
![Western Blot: CHREBP Antibody - BSA Free [NB400-135] - Decreased glucose uptake & Chrebp beta -driven DNL is a primary consequence of Rictor loss in adipocytes.(a) Western blots of indicated proteins at different days of differentiation using Rictor iKO primary adipocytes (described in Methods). (b) Oil Red O staining of differentiated adipocytes. (c) The relative mRNA level of ChREBP beta in differentiated cells at various time points. n=3. (d) 2-DG uptake in differentiated adipocytes without or with insulin stimulation. n=3. (e) The C14-glucose-derived FA in differentiated adipocytes. n=3. (f) The C14-glucose derived triglyceride (TAG) in differentiated adipocytes. n=3. (g) Relative glut4 expression in differentiated cells at various time points. n=3. (h) Relative glut4 expression in sWAT. n=8. (i) Glycerol release in differentiated adipocytes under basal & isoproterenol (Iso) stimulation. n=4. (j) Glycerol release in ex vivo pgWAT under basal & isoproterenol stimulation. n=6. Data were analysed by Student's t-test. Values are expressed as mean+s.e.m. *P<0.05; **P<0.01; ***P<0.001. Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/ncomms11365), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-135_rabbit-polyclonal-chrebp-antibody-310202416163714.jpg)
![Western Blot: CHREBP Antibody - BSA Free [NB400-135] - RetSat controls ChREBP activity & glucose sensing in primary hepatocytes. Primary mouse hepatocytes were treated with Control or RetSat siRNA for 48 h, (a, left) ChREBP mRNA expression determined by qPCR, & RetSat & ChREBP protein levels determined by immunoblotting (a, right). left, Data are shown as mean ± 11s.d., n = 3 independent transfections of hepatocyte cultures from the same mouse. Two independent experiments yielded similar results. b Hepatocytes were treated as described in a & mRNA expression of a selection of known ChREBP target genes visualized in a heatmap. c Primary hepatocytes were depleted of RetSat using two siRNA’s targeting different sites of the RetSat transcript for 48 h, & expression of the indicated genes analyzed by qPCR. Data are shown as mean ± s.d., n = 6 independent transfections of hepatocyte cultures from two different mice; *P < 0.05 between siControl und siRetSat by one-way ANOVA with Bonferroni post test. An independent experiment yielded similar results. d Hepatocytes treated with Control or RetSat siRNA were transfected with a ChoRE-Luc reporter, exposed to low & high glucose concentrations as indicated, & analyzed for luciferase activity. e Hepatocytes treated with Control or RetSat siRNA were exposed to low & high glucose concentrations as indicated, & mRNA expression determined by qPCR. In d, e, data are shown as mean ± s.d., n = 6 independent transfections of hepatocyte cultures from two mice; two-way ANOVA with Bonferroni post test revealed significances between low & high glucose concentrations (#P < 0.05) & between siControl & siRetSat (*P < 0.05). An independent experiment yielded similar results Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-017-00430-w), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-135_rabbit-polyclonal-chrebp-antibody-310202416165648.jpg)
![Western Blot: CHREBP Antibody - BSA Free [NB400-135] - LXR alpha & ChREBP alpha interact via key activation domains. (A). Top panel: Schematic representation of the ChREBP alpha full-length (FL), ChREBP beta & the low glucose inhibitory domain (LID) protein. Bottom panel: CoIP of LXR alpha & ChREBP alpha , ChREBP beta or LID, expressed in COS-1 cells cultured in 25 mM glucose. The ChREBP expression plasmids were transfected with a DNA ratio of ChREBP alpha :ChREBP beta :LID = 1:6:1, to obtain comparable protein levels. Lysates were immunoprecipitated with ChREBP, FLAG (for LID) or LXR alpha antibodies & input & immunoprecipitated proteins immunoblotted with the same antibodies (n = 3). One representative western blot is shown. LID, low-glucose inhibitory domain; GRACE, glucose-response activation conserved element; bHLH, basic helix-loop-helix domain: ZIP, leucine zipper. (B). Top panel: Schematic representation of the LXR alpha FL & truncations. Bottom panel: CoIP of ChREBP alpha & LXR alpha FL or truncations expressed in COS-1 cells cultured in 25 mM glucose. Lysates were immunoprecipitated with ChREBP antibody (n = 3). Input & immunoprecipitated proteins were immunoblotted with ChREBP or FLAG (for LXR alpha FL & truncations) antibodies. One representative western blot is shown. NTD, N-terminal domain; DBD, DNA-binding domain; LBD, ligand-binding domain. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32414201), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-135_rabbit-polyclonal-chrebp-antibody-310202416175271.jpg)
![Western Blot: CHREBP Antibody - BSA Free [NB400-135] - FXR inhibits glucose-induced proglucagon expression(a) Proglucagon qPCR on cDNA from GLUTag cells starved for 12h with lactate (10 mmol L−1) & then incubated for 24h in lactate (10 mmol L−1), glucose (5.6 mmol L−1) or 2-deoxyglucose (5.6 mmol L−1) media containing DMSO, GW4064 (5 μmol L−1) or CDCA (100 μmol L−1) (n=3; performed 3 times). Data are represented as mean +/− SD. Two-Way ANOVA analysis followed by Bonferronni’s posthoc test. ***P≤0.001: effect of GW4064 & CDCA on proglucagon mRNA levels in each medium conditions. §§§P≤0.001: effect of glucose on proglucagon mRNA levels in DMSO, GW4064 & CDCA conditions. (b) Chrebp qPCR on cDNA from FACS-sorted proglucagon-negative & proglucagon-positive cells from the ileum (ileum L−; ileum L+) & colon (colon L−; colon L+) of GLU-VENUS mice (lower panel; n=3) & ChREBP protein expression from cytoplasm & nucleus extract from GLUTag cells (upper panel; performed 3 times). Data are represented as mean +/− SD. Student t-test. *P≤0.05 & **P≤0.01 (c) ChREBP & FXR western-blots after FXR immunoprecipitation on lysates from cytoplasm & nucleus of GLUTag cells treated or not with GW4064 (5 μmol L-1) in presence or not of glucose (5.6 mmol L−1) (performed 2 times). (d) Proglucagon qPCR on cDNA from GLUTag cells electroporated with a siCtrl or siChrebp, starved for 12h with lactate (10 mmol L−1) & then incubated for 24h in lactate 10 mmol L−1 (Glc −) or glucose 5.6 mmol L−1 (Glc +) media supplemented with DMSO or GW4064 (5 μmol L−1) (n=3; performed 3 times). Data are represented as mean +/− SD. Two-Way ANOVA analysis followed by Bonferronni’s posthoc test. *P≤0.05 & **P≤0.01: effect of treatments on each transfection condition. §§§P≤0.001: effect of siChrebp in each treatment condition. Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/ncomms8629), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-135_rabbit-polyclonal-chrebp-antibody-31020241616057.jpg)
![Western Blot: CHREBP Antibody - BSA Free [NB400-135] - Dietary fructose induces nuclear O-GlcNAc signaling. (A) Simplified schematic overview of the hexosamine signaling pathway including the rate limiting enzyme GFAT & O-GlcNAc transferase (OGT); (B) High-performance liquid chromatography (HPLC) analysis of hepatic UDP-GlcNAc levels. Left panel: Example of a typical running profile w/ or w/out injection of UDP-GlcNAc standard (Std.) is shown. Right panel: Quantification of the HPLC data normalized to protein concentration; (C) Hepatic expression of the Ogt gene & cytosolic & nuclear OGT protein analyzed by quantitative RT-PCR & western blotting/Image J & normalized to Tbp, alpha -tubulin, & Lamin A, respectively. Data represent the mean ± SEM (n = 5); (D) Cytosolic & nuclear lysates immunoblotted w/ anti-O-GlcNAc antibody (RL2) w/ alpha -Tubulin & Lamin A as loading controls. Each lane represents independent mice from each group. One representative western blot is shown (n = 2); (E) Nuclear lysates subjected to wheat germ agglutinin (WGA) beads to precipitate O-GlcNAcylated proteins. WGA enriched samples (upper panel) & input lysates (bottom panel) immunoblotted w/ antibodies detecting O-GlcNAcylated proteins (RL2), LXR & ChREBP. Each lane represents independent mice from experimental groups. Representative western blots are shown (n = 2); (F) ChREBP binding to carbohydrate response element (ChoRE) containing region of the L-pk promoter & negative control sequence (NC) 2216–2288 bp into L-pk gene after ChoRE sequence detected by chromatin immunoprecipitation (ChIP) using antibodies against ChREBP or IgG as a control. Data represent the mean ± SEM (n = 5). Significant differences found using two-way ANOVA followed by Tukey’s multiple comparison test. ** p < 0.01 compared to fasted. Image collected & cropped by CiteAb from the following publication (//www.mdpi.com/2072-6643/9/7/678), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-135_rabbit-polyclonal-chrebp-antibody-310202416171465.jpg)
![Immunohistochemistry-Paraffin: CHREBP Antibody - BSA Free [NB400-135] - Correction of hepatic G6Pase-alpha deficiency normalizes autophagy.L-G6pc-/- mice were treated with 1 x 1012 vp/kg of rAAV-G6PC at 4 WP & analyzed at 12 WP. (A) Hepatic G6Pase-alpha activity in control (n = 7), L-G6pc-/- (n = 7), & rAAV-treated L-G6pc-/- (AAV/ L-G6pc-/-, n = 8) mice. (B) Liver weights in control (n = 10), L-G6pc-/- (n = 5), & AAV/ L-G6pc-/- (n = 8) mice. (C) The levels of hepatic metabolites in control, L-G6pc-/- & AAV/ L-G6pc-/- (n = 8) mice. (D) Fasting glucose test (FGT) profile of control (n = 13), L-G6pc-/- (n = 6) & AAV/ L-G6pc-/- (n = 8) mice. (E) Western blots of hepatic SIRT1, FoxO3a, LC3B, p62 & beta -actin & densitometry analysis (n = 8). (F) Hematoxylin & eosin (H&E) stained liver sections, & immunohistochemical analysis of hepatic ChREBP & quantification of nuclear ChREBP-translocated cells in control, L-G6pc-/-, & rAAV-treated L-G6pc-/- (AAV/ L-G6pc-/-) mice (n = 4). The insets present higher magnification views. Scale bar, 25 μm. Data represent the mean ± SEM. *P < 0.05, **P < 0.005. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28558013), licensed under a CC0-1.0 license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-135_rabbit-polyclonal-chrebp-antibody-310202416175247.jpg)
![Western Blot: CHREBP Antibody - BSA Free [NB400-135] - Phf2 expression is increased in the liver of obese patients with benign hepatic steatosis & positively correlates with insulin sensitivity. Human liver biopsies from lean subjects with no fatty liver (NoFL) or obese patients with simple steatosis or NASH were obtained from the ABOS cohort. a Representative Western blot analysis of Phf2, ChREBP, SCD1, Nrf2, Gpx4, & alpha -SMA expression (n = 10 per group). b ChIP experiments for H3K9me2 levels & for the recruitment of ChREBP & the RNA polII at the SCD1 & Nrf2 promoter (n = 10 per group). c MUFA/SFA ratio reflecting SCD1 activity (n = 10 per group). d Expression of Nrf2 & Nrf2-regulated genes (n = 10 per group). e Levels of carbonylated proteins (n = 10 per group). f Expression of coll-Ia1, alpha -SMA, & TIMP-1 (n = 10 per group). All error bars represent mean ± SEM. Statistical analyses were made using Anova, followed by Bonferonni’s test. *Obese with steatosis compared to lean with noFL; P < 0.01. **Obese with steatosis compared to obese with NASH; P < 0.05 Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-018-04361-y), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb400-135_rabbit-polyclonal-chrebp-antibody-310202416163772.jpg)
![Western Blot: Snail Antibody [NBP2-27293] - Cisplatin-resistant gastric cancer cells exhibit an EMT-like phenotypic change. Epithelial marker E-cadherin, ZO1 and EMT-related transcription factor Snail were examined by Western blot. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep20502), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Snail-Antibody-Western-Blot-NBP2-27293-img0005.jpg "Western Blot: Snail Antibody [NBP2-27293] - Cisplatin-resistant gastric cancer cells exhibit an EMT-like phenotypic change. Epithelial marker E-cadherin, ZO1 and EMT-related transcription factor Snail were examined by Western blot. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep20502), licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: Snail Antibody [NBP2-27293] - Analysis of a FFPE tissue section of mouse placenta using 1:200 dilution of SNAIL antibody. The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/Snail-Antibody-Immunohistochemistry-Paraffin-NBP2-27293-img0007.jpg)
![Western Blot: Snail Antibody [NBP2-27293] - HER2 is overexpressed and both Herceptin incubation and siRNAs against HER2 reversed the EMT in cisplatin-resistant gastric cancer cells. Effects of Herceptin on levels of ZO1 and Snail. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep20502), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Snail-Antibody-Western-Blot-NBP2-27293-img0006.jpg)
![Immunohistochemistry-Paraffin: Snail Antibody [NBP2-27293] - Analysis of in FFPE human kidney tissue using this antibody at 5 ug/mL.](http://images.novusbio.com/fullsize/Snail-Antibody-Immunohistochemistry-Paraffin-NBP2-27293-img0004.jpg)
![Simple Western: Snail Antibody [NBP2-27293] - Image shows a specific band for SNAIL in 0.5 mg/mL of MCF-7 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/Snail-Antibody-Simple-Western-NBP2-27293-img0002.jpg)
![Western Blot: Snail Antibody - BSA Free [NBP2-27293] - SiRNAs against HER2 could abrogate the EMT phenotype & cell invasiveness in cisplatin-resistant gastric cancer cells.(A) Validation of silencing efficiency of HER2. Cells were transiently transfected with 50 nM HER2-specific siRNAs #1-#3 or a control siRNA for 48 h. (B) Knock-down of HER2 abrogated EMT morphology. Cells were transiently transfected with 50 nM specific siRNAs targeting HER2 for 48 h, Representative images of cellular morphology were shown. (C) Knock-down of HER2 abolished EMT phenotype. Cells were treated as in Fig. 4B. FITC-phalloidin staining of F-actin were performed & representative images were shown. (D) Effects of HER2 knock-down on the levels of ZO1 & Snail. (E) Effects of HER2 knock-down on cell migration. Representative images of transwell cell migration assay were shown. (F) Summary of Fig. 4E. Values represented the mean ± SD from three independent experiments with triplicate samples. *P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26846307), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-27293_rabbit-polyclonal-snail-antibody-310202416114759.jpg)
![Western Blot: Snail Antibody - BSA Free [NBP2-27293] - HER2 is overexpressed & both Herceptin incubation & siRNAs against HER2 reversed the EMT in cisplatin-resistant gastric cancer cells.(A) Western blot of HER2 in MGC803/DDP & AGS/DDP cell lines, & parental MGC803 & AGS cells. GAPDH was used as loading control. (B) Relative amplification of HER2 in parental & cisplatin-resistant cells. Results were presented as the mean ± SD of two independent experiments, *P < 0.05 compared with parental cells. (C) Herceptin incubation abrogated EMT morphology in MGC803/DDP cells. Representative images of cellular morphology of MGC803/DDP cells, plus parental MGC803 cells treated with Herceptin for 24 h were shown. Hercep represents Herceptin. (D) Herceptin incubation reversed EMT morphology in MGC803/DDP cells. Representative images of FITC-phalloidin staining of F-actin after 100 μg/ml Herceptin treatment for 24 h were shown. (E) Effects of Herceptin on levels of ZO1 & Snail. (F) CP724714 treatment abolished EMT-like cell morphology. Cells were incubated with 10 μM CP724714 for 24 h. Representative images of cellular morphology of were captured. (G) CP724714 treatment abrogated EMT-like cell morphology. Cells were treated as in Fig. 4F, FITC-phalloidin staining of F-actin was performed & typical images were shown. (H) Effects of CP724714 on ZO1 & Snail. (I) CP724714 inhibited the increased cell migration in cisplatin-resistant gastric cancer cells. Representative images were presented here. (J) CP724714 inhibited the increased cell migration in cisplatin-resistant gastric cancer cells. Values represented the mean ± SD from three independent experiments with triplicate samples. *P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26846307), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-27293_rabbit-polyclonal-snail-antibody-310202416113529.jpg)
![Western Blot: PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - Analysis of human tonsil (1), human spleen (2), and human lymph node (3) tissue using CD162 antibody at a concentration of 2 ug/ml.](http://images.novusbio.com/fullsize/Cutaneous-Lymphocyte-Antigen-CLA-Antibody-HECA-452-Western-Blot-NB100-78039-img0006.jpg "Western Blot: PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - Analysis of human tonsil (1), human spleen (2), and human lymph node (3) tissue using CD162 antibody at a concentration of 2 ug/ml.")
![Immunohistochemistry-Paraffin: PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Human tonsil tissue stained with PSGL-1/CD162 Antibody (HECA-452) at 5ug/mL, and Leica Refine DAB kit. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/PSGL-1-CD162-Antibody-HECA-452-Immunohistochemistry-Paraffin-NB100-78039-img0014.jpg)
![Flow (Cell Surface): PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - A cell surface stain was performed on CD3+ hPBMCs with Cutaneous Lymphocyte Antigen (CLA) antibody (HECA-452) NB100-78039 and a matched isotype control NBP2-31379. Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) APC-conjugated secondary antibody [F0101B, R&D Systems]. A co-stain was performed using CD3 antibody NBP2-25186APC.](http://images.novusbio.com/fullsize/Cutaneous-Lymphocyte-Antigen-CLA-Antibody-HECA-452-Flow-Cell-Surface-NB100-78039-img0008.jpg)
![Immunohistochemistry-Paraffin: PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - IHC analysis of formalin-fixed paraffin-embedded tissue section of human breast adenocarcinoma using CLA antibody (clone HECA-452) at 5 ug/ml concentration. The antibody generated a membrane-cytoplasmic staining in the cancerous cells of breast adenocarcinoma. Note:- Besides lymphocytes, CLA has been shown to be present on cells of normal endometrium as well as breast cancer tissues (PMID 19625313 and 22970241).](http://images.novusbio.com/fullsize/Cutaneous-Lymphocyte-Antigen-CLA-Antibody-HECA-452-Immunohistochemistry-Paraffin-NB100-78039-img0004.jpg)
![Flow Cytometry: PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - Human peripheral blood lymphocytes stained with purified HECA-452, followed by anti-mouse IgG FITC](http://images.novusbio.com/fullsize/Cutaneous-Lymphocyte-Antigen-CLA-Antibody-HECA-452-Flow-Cytometry-NB100-78039-img0005.jpg)
![Flow (Cell Surface): PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - A cell surface stain was performed on CD14+ hPBMCs with Cutaneous Lymphocyte Antigen (CLA) antibody (HECA-452) NB100-78039 and a matched isotype control NBP2-31379. Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature, followed by rat-Dylight 488 conjugated secondary antibody. A co-stain was performed using CD14 antibody NB100-77758AF488.](http://images.novusbio.com/fullsize/Cutaneous-Lymphocyte-Antigen-CLA-Antibody-HECA-452-Flow-Cell-Surface-NB100-78039-img0007.jpg)
![Western Blot: VLDLR Antibody (6A6) [NBP1-78162] - MCF-7 cells were exposed to 20% or 1% O2 for 48 hours, whole cell lysates were loaded with 50 ug/lane. 10% SDS-PAGE. VLDLR Antibody (NBP1-78162) antibody at 1:1000, 4C, overnight. WB image submitted by a verifed customer review.](http://images.novusbio.com/fullsize/VLDLR-Antibody-6A6-Western-Blot-NBP1-78162-img0010.jpg "Western Blot: VLDLR Antibody (6A6) [NBP1-78162] - MCF-7 cells were exposed to 20% or 1% O2 for 48 hours, whole cell lysates were loaded with 50 ug/lane. 10% SDS-PAGE. VLDLR Antibody (NBP1-78162) antibody at 1:1000, 4C, overnight. WB image submitted by a verifed customer review.")
![Immunocytochemistry/Immunofluorescence: VLDLR Antibody (6A6) [NBP1-78162] - VLDL R Antibody (6A6) [NBP1-78162] - VLDL Receptor antibody was tested in HeLa cells with FITC (green). Nuclei and actin were counterstained with DAPI (blue) and Phalloidin (red).](http://images.novusbio.com/fullsize/VLDL-R-Antibody-6A6-Immunocytochemistry-Immunofluorescence-NBP1-78162-img0006.jpg)
![Immunohistochemistry: VLDL R Antibody (6A6) [NBP1-78162] - Analysis of VLDL Receptor in mouse kidney.](http://images.novusbio.com/fullsize/VLDL-R-Antibody-6A6-Immunohistochemistry-NBP1-78162-img0007.jpg)
![Western Blot: VLDL R Antibody (6A6) [NBP1-78162] - Analysis of VLDL Receptor expression in mouse kidney.](http://images.novusbio.com/fullsize/VLDL-R-Antibody-6A6-Western-Blot-NBP1-78162-img0008.jpg)
![Western Blot: Snail Antibody [NBP1-80022] - Host: Mouse. Target Name: SNAI1. Sample Tissue: Mouse Spleen. Antibody Dilution: 1ug/ml](http://images.novusbio.com/fullsize/Snail-Antibody-Western-Blot-NBP1-80022-img0007.jpg "Western Blot: Snail Antibody [NBP1-80022] - Host: Mouse. Target Name: SNAI1. Sample Tissue: Mouse Spleen. Antibody Dilution: 1ug/ml")
![Immunohistochemistry-Paraffin: Snail Antibody [NBP1-80022] - Rabbit Anti-SNAI1 Antibody. Formalin Fixed Paraffin Embedded Tissue: Human Urinary Bladder Tissue. Observed Staining: Cytoplasm. Primary Antibody Concentration: 1:100. Secondary Antibody: Donkey anti-Rabbit-Cy3. Secondary Antibody Concentration: 1:200. Ma](http://images.novusbio.com/fullsize/Snail-Antibody-Immunohistochemistry-Paraffin-NBP1-80022-img0006.jpg)
![Western Blot: Snail Antibody [NBP1-80022] - 721_B cell lysate, Antibody Titration: 1ug/ml](http://images.novusbio.com/fullsize/Snail-Antibody-Western-Blot-NBP1-80022-img0002.jpg)
![Western Blot: Snail Antibody [NBP1-80022] - Antibody Titration: 1 ug/ml Human 721_B.](http://images.novusbio.com/fullsize/Snail-Antibody-Western-Blot-NBP1-80022-img0004.jpg)
![Western Blot: Snail Antibody [NBP1-80022] - Antibody Titration: 1 ug/ml Human A549.](http://images.novusbio.com/fullsize/Snail-Antibody-Western-Blot-NBP1-80022-img0005.jpg)
![Immunohistochemistry-Paraffin: Snail Antibody [NBP1-80022] - Human kidney Tissue, antibody concentration 4-8ug/ml. Cells with positive label: renal corpuscle cells (indicated with arrows) 400X magnification.](http://images.novusbio.com/fullsize/Snail-Antibody-Immunohistochemistry-Paraffin-NBP1-80022-img0003.jpg)
![Western Blot: Sphingosine Kinase 1/SPHK1 Antibody (1D6) [H00008877-M01] - SPHK1 monoclonal antibody (M01), clone 1D6. Analysis of SPHK1 expression in K-562.](http://images.novusbio.com/fullsize/Sphingosine-Kinase-1-SPHK1-Antibody-1D6-Western-Blot-H00008877-M01-img0005.jpg "Western Blot: Sphingosine Kinase 1/SPHK1 Antibody (1D6) [H00008877-M01] - SPHK1 monoclonal antibody (M01), clone 1D6. Analysis of SPHK1 expression in K-562.")
![Western Blot: Sphingosine Kinase 1/SPHK1 Antibody (1D6) [H00008877-M01] - SPHK1 monoclonal antibody (M01), clone 1D6 Western Blot analysis of SPHK1 expression in A-431 ( Cat # L015V1 ).](http://images.novusbio.com/fullsize/Sphingosine-Kinase-1-SPHK1-Antibody-1D6-Western-Blot-H00008877-M01-img0002.jpg)
![Western Blot: Sphingosine Kinase 1/SPHK1 Antibody (1D6) [H00008877-M01] - Analysis of SPHK1 expression in transfected 293T cell line by SPHK1 monoclonal antibody (M01), clone 1D6.Lane 1: SPHK1 transfected lysate(43.9 KDa).Lane 2: Non-transfected lysate.](http://images.novusbio.com/fullsize/Sphingosine-Kinase-1-SPHK1-Antibody-1D6-Western-Blot-H00008877-M01-img0006.jpg)
![ELISA: Sphingosine Kinase 1/SPHK1 Antibody (1D6) [H00008877-M01] - Detection limit for recombinant GST tagged SPHK1 is approximately 1ng/ml as a capture antibody.](http://images.novusbio.com/fullsize/Sphingosine-Kinase-1-SPHK1-Antibody-1D6-ELISA-H00008877-M01-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: CHREBP Antibody (2D9NB) [NBP2-44307] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with CHREBP (2D9NB) at a 1:100 dilution overnight at 4C and detected with DyLight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were detected with DAPI (Blue) at 2.0 ug/ml in 1X PBS. Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/CHREBP-Antibody-2D9NB-Immunocytochemistry-Immunofluorescence-NBP2-44307-img0001.jpg "Immunocytochemistry/Immunofluorescence: CHREBP Antibody (2D9NB) [NBP2-44307] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with CHREBP (2D9NB) at a 1:100 dilution overnight at 4C and detected with DyLight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were detected with DAPI (Blue) at 2.0 ug/ml in 1X PBS. Cells were imaged using a 40X objective.")
![Immunohistochemistry-Paraffin: CHREBP Antibody (2D9NB) [NBP2-44307] - Analysis of a FFPE tissue section of human hepatocellular carcinoma using 1:200 dilution of CHREBP antibody (clone 2D9NB). The antibody generated a diffused to punctate staining pattern in the cytoplasm of cancer cells. Some cells depicted nuclear positivity also while the stroma was largely negative for CHREBP expression.](http://images.novusbio.com/fullsize/CHREBP-Antibody-2D9NB-Immunohistochemistry-Paraffin-NBP2-44307-img0003.jpg)
![Immunohistochemistry-Paraffin: CHREBP Antibody (2D9NB) [NBP2-44307] - Analysis of a FFPE tissue section of normal human kidney using 1:200 dilution of CHREBP antibody (clone 2D9NB). The antibody generated a diffused to punctate staining pattern mainly in the cytoplasm (but in some nuclei also) of cuboidal epithelial cells of various ducts and tubules.](http://images.novusbio.com/fullsize/CHREBP-Antibody-2D9NB-Immunohistochemistry-Paraffin-NBP2-44307-img0002.jpg)
![Western Blot: Snail Antibody [NBP2-27184] - Analysis of function protein expression on primary human renal cortical epithelial cells challenged with cytokines. Primary human renal tubular epithelial cells are challenged with cytokine cocktail (15nM IFN gamma, 6nM TNF alpha, and 3nM IL1 beta). Expression of Snail (NBP2-27184SS), E-Cad, TJP1, SMA. AhR, IDO, KMO, KY, MHCI & II. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/34305900/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Snail-Antibody-Western-Blot-NBP2-27184-img0006.jpg "Western Blot: Snail Antibody [NBP2-27184] - Analysis of function protein expression on primary human renal cortical epithelial cells challenged with cytokines. Primary human renal tubular epithelial cells are challenged with cytokine cocktail (15nM IFN gamma, 6nM TNF alpha, and 3nM IL1 beta). Expression of Snail (NBP2-27184SS), E-Cad, TJP1, SMA. AhR, IDO, KMO, KY, MHCI & II. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/34305900/) licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: Snail Antibody [NBP2-27184] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with SNAIL (NBP2-27184) at a 1:100 dilution overnight at 4 degrees Celsius and detected with DyLight 488 (Green) at a 1:500 dilution. Alpha tubulin was used as a co-stain at a 1:1000 dilution and detected with DyLight 550 (Red). Nuclei were detected with DAPI (Blue) at 2.0 ug/ml in 1X PBS. Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/Snail-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-27184-img0005.jpg)
![Western Blot: Snail Antibody [NBP2-27184] - Analysis of Snail in human MCF7 cell lysate using (1) prebleed at 1:5000 dilution and (2) this antibody. Goat anti-rabbit Ig HRP secondary antibody and PicoTect ECL substrate solution were used for this test.](http://images.novusbio.com/fullsize/Snail-Antibody-Western-Blot-NBP2-27184-img0003.jpg)
![Western Blot: Aldehyde Dehydrogenase 1-A1/ALDH1A1 Antibody [NBP2-15336] - PG-4 whole cell extract (30 ug) was separated by 10% SDS-PAGE, and the membrane was blotted with ALDH1A1 antibody diluted at 1:10000. The HRP-conjugated anti-rabbit IgG antibody (NBP2-19301) was used to detect the primary antibody.](http://images.novusbio.com/fullsize/Aldehyde-Dehydrogenase-1-A1-ALDH1A1-Antibody-Western-Blot-NBP2-15336-img0021.jpg "Western Blot: Aldehyde Dehydrogenase 1-A1/ALDH1A1 Antibody [NBP2-15336] - PG-4 whole cell extract (30 ug) was separated by 10% SDS-PAGE, and the membrane was blotted with ALDH1A1 antibody diluted at 1:10000. The HRP-conjugated anti-rabbit IgG antibody (NBP2-19301) was used to detect the primary antibody.")
![Immunocytochemistry/Immunofluorescence: Aldehyde Dehydrogenase 1-A1/ALDH1A1 Antibody [NBP2-15336] - Analysis of methanol-fixed A549, using antibody at 1:500 dilution.](http://images.novusbio.com/fullsize/ALDH1A1-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-15336-img0001.jpg)
![Western Blot: Aldehyde Dehydrogenase 1-A1/ALDH1A1 Antibody [NBP2-15336] - Detects ALDH1A1 protein by Western blot analysis. A. 50 ug rat liver lysate/extract 10 % SDS-PAGE Dilution: 1:5000](http://images.novusbio.com/fullsize/ALDH1A1-Antibody-Western-Blot-NBP2-15336-img0012.jpg)
![Western Blot: Aldehyde Dehydrogenase 1-A1/ALDH1A1 Antibody [NBP2-15336] - Detects ALDH1A1 protein by Western blot analysis. A. 50 ug mouse liver lysate/extract 10 % SDS-PAGE Dilution: 1:5000](http://images.novusbio.com/fullsize/ALDH1A1-Antibody-Western-Blot-NBP2-15336-img0015.jpg)
![Western Blot: Aldehyde Dehydrogenase 1-A1/ALDH1A1 Antibody [NBP2-15336] - Various whole cell extracts (30 ug) were separated by 10% SDS-PAGE, and the membrane was blotted with ALDH1A1 antibody diluted at 1:10000. The HRP-conjugated anti-rabbit IgG antibody (NBP2-19301) was used to detect the primary antibody.](http://images.novusbio.com/fullsize/Aldehyde-Dehydrogenase-1-A1-ALDH1A1-Antibody-Western-Blot-NBP2-15336-img0018.jpg)
![Immunohistochemistry-Paraffin: Aldehyde Dehydrogenase 1-A1/ALDH1A1 Antibody [NBP2-15336] - Human gastric cancer, using ALDH1A1 antibody at 1:500 dilution. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min.](http://images.novusbio.com/fullsize/ALDH1A1-Antibody-Immunohistochemistry-Paraffin-NBP2-15336-img0002.jpg)
![Western Blot: Muscle Phosphofructokinase/PFKM/PFK-1 Antibody (JU53-31) [NBP2-75578] - Western blot analysis of Muscle Phosphofructokinase/PFKM/PFK-1 on different lysates. Proteins were transferred to a PVDF membrane and blocked with 5% BSA in PBS for 1 hour at room temperature. The primary antibody (1/500) was used in 5% BSA at room temperature for 2 hours. Goat Anti-Rabbit IgG - HRP Secondary Antibody (HA1001) at 1:5,000 dilution was used for 1 hour at room temperature. Positive control: Lane 1: HepG2 cell lysate Lane 2: PC-3M cell lysate](http://images.novusbio.com/fullsize/Muscle-Phosphofructokinase-PFKM-PFK-1-Antibody-JU53-31-Western-Blot-NBP2-75578-img0011.jpg "Western Blot: Muscle Phosphofructokinase/PFKM/PFK-1 Antibody (JU53-31) [NBP2-75578] - Western blot analysis of Muscle Phosphofructokinase/PFKM/PFK-1 on different lysates. Proteins were transferred to a PVDF membrane and blocked with 5% BSA in PBS for 1 hour at room temperature. The primary antibody (1/500) was used in 5% BSA at room temperature for 2 hours. Goat Anti-Rabbit IgG - HRP Secondary Antibody (HA1001) at 1:5,000 dilution was used for 1 hour at room temperature. Positive control: Lane 1: HepG2 cell lysate Lane 2: PC-3M cell lysate")
![Immunocytochemistry/Immunofluorescence: Muscle Phosphofructokinase/PFKM/PFK-1 Antibody (JU53-31) [NBP2-75578] - Staining Fructose 6 Phosphate Kinase in SH-SY-5Y cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.](http://images.novusbio.com/fullsize/Muscle-Phosphofructokinase-PFKM-PFK-1-Antibody-JU53-31-Immunocytochemistry-Immunofluorescence-NBP2-75578-img0004.jpg)
![Immunohistochemistry-Paraffin: Muscle Phosphofructokinase/PFKM/PFK-1 Antibody (JU53-31) [NBP2-75578] - Analysis of paraffin-embedded rat brain tissue using anti-Fructose 6 Phosphate Kinase antibody. Counter stained with hematoxylin.](http://images.novusbio.com/fullsize/Muscle-Phosphofructokinase-PFKM-PFK-1-Antibody-JU53-31-Immunohistochemistry-Paraffin-NBP2-75578-img0009.jpg)
![Flow Cytometry: Muscle Phosphofructokinase/PFKM/PFK-1 Antibody (JU53-31) [NBP2-75578] - Analysis of SH-SY-5Y cells with Fructose 6 Phosphate Kinase antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black). Alexa Fluor 488-conjugated goat anti-rabbit IgG was used as the secondary antibody.](http://images.novusbio.com/fullsize/Muscle-Phosphofructokinase-PFKM-PFK-1-Antibody-JU53-31-Flow-Cytometry-NBP2-75578-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: Muscle Phosphofructokinase/PFKM/PFK-1 Antibody (JU53-31) [NBP2-75578] - Staining Fructose 6 Phosphate Kinase in LOVO cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.](http://images.novusbio.com/fullsize/Muscle-Phosphofructokinase-PFKM-PFK-1-Antibody-JU53-31-Immunocytochemistry-Immunofluorescence-NBP2-75578-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: Muscle Phosphofructokinase/PFKM/PFK-1 Antibody (JU53-31) [NBP2-75578] - Staining Fructose 6 Phosphate Kinase in PC-3M cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.](http://images.novusbio.com/fullsize/Muscle-Phosphofructokinase-PFKM-PFK-1-Antibody-JU53-31-Immunocytochemistry-Immunofluorescence-NBP2-75578-img0003.jpg)
![Immunohistochemistry-Paraffin: Muscle Phosphofructokinase/PFKM/PFK-1 Antibody (JU53-31) [NBP2-75578] - Analysis of paraffin-embedded human liver cancer tissue using anti-Fructose 6 Phosphate Kinase antibody. Counter stained with hematoxylin.](http://images.novusbio.com/fullsize/Muscle-Phosphofructokinase-PFKM-PFK-1-Antibody-JU53-31-Immunohistochemistry-Paraffin-NBP2-75578-img0005.jpg)
![Immunohistochemistry-Paraffin: Muscle Phosphofructokinase/PFKM/PFK-1 Antibody (JU53-31) [NBP2-75578] - Analysis of paraffin-embedded human thyroid gland tissue using anti-Fructose 6 Phosphate Kinase antibody. Counter stained with hematoxylin.](http://images.novusbio.com/fullsize/Muscle-Phosphofructokinase-PFKM-PFK-1-Antibody-JU53-31-Immunohistochemistry-Paraffin-NBP2-75578-img0006.jpg)
![Immunohistochemistry-Paraffin: Muscle Phosphofructokinase/PFKM/PFK-1 Antibody (JU53-31) [NBP2-75578] - Analysis of paraffin-embedded human kidney tissue using anti-Fructose 6 Phosphate Kinase antibody. Counter stained with hematoxylin.](http://images.novusbio.com/fullsize/Muscle-Phosphofructokinase-PFKM-PFK-1-Antibody-JU53-31-Immunohistochemistry-Paraffin-NBP2-75578-img0007.jpg)
![Immunohistochemistry-Paraffin: Muscle Phosphofructokinase/PFKM/PFK-1 Antibody (JU53-31) [NBP2-75578] - Analysis of paraffin-embedded mouse skeletal muscle tissue using anti-Fructose 6 Phosphate Kinase antibody. Counter stained with hematoxylin.](http://images.novusbio.com/fullsize/Muscle-Phosphofructokinase-PFKM-PFK-1-Antibody-JU53-31-Immunohistochemistry-Paraffin-NBP2-75578-img0008.jpg)
![Western Blot: SNAIL Antibody [NBP2-29626] - Western blot analysis of SNAIL in HeLa whole cell extract.](http://images.novusbio.com/fullsize/SNAIL-Antibody-Western-Blot-NBP2-29626-img0001.jpg "Western Blot: SNAIL Antibody [NBP2-29626] - Western blot analysis of SNAIL in HeLa whole cell extract.")
![Immunocytochemistry/Immunofluorescence: CHREBP Antibody [NB400-136] - Staining of a human hepatocyte using NB400-136. Overlay staining of ChREBP (rhodamine red) and DAPI nuclear staining (blue).](http://images.novusbio.com/fullsize/CHREBP-Antibody-Immunocytochemistry-Immunofluorescence-NB400-136-img0002.jpg "Immunocytochemistry/Immunofluorescence: CHREBP Antibody [NB400-136] - Staining of a human hepatocyte using NB400-136. Overlay staining of ChREBP (rhodamine red) and DAPI nuclear staining (blue).")